Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.77 |
| ▸ | CTSL | P07711 | 2/20 | 0.76 |
| ▸ | CTSS | P25774 | 1/20 | 0.76 |
| ▸ | CTSK | P43235 | 1/20 | 0.76 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.70 |
| ▸ | TACR1 | P25103 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.62 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.62 |
| ▸ | ITGAL | P20701 | 1/20 | 0.62 |
| ▸ | ECE1 | P42892 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29367687 | 1.00 | ACE (0.77) | ACECTSLCTSSCTSKSCN9A | |
| SCHEMBL850438 | 1.00 | ACE (0.77) | ACECTSLCTSSCTSKSCN9A | |
| SCHEMBL1486167 | 1.00 | ACE (0.77) | ACECTSLCTSSCTSKSCN9A | |
| SCHEMBL30976323 | 1.00 | ACE (0.77) | ACECTSLCTSSCTSKSCN9A | |
| Hydrochloric Acid SCHEMBL31472643 | 0.99 | ACE (0.75) | ACECTSLCTSSCTSKSCN9A | |
| SCHEMBL30699849 | 0.99 | ACE (0.75) | ACECTSLCTSSCTSKSCN9A | |
| Fluoride SCHEMBL7445962 | 0.99 | ACE (0.75) | ACECTSLCTSSCTSKSCN9A | |
| Fluoride SCHEMBL7445954 | 0.99 | ACE (0.75) | ACECTSLCTSSCTSKSCN9A | |
| SCHEMBL11403615 | 0.96 | ACE (0.84) | ACECTSLCTSSCTSKSCN9A | |
| SCHEMBL27871524 | 0.96 | CTSL (0.76) | ACECTSLCTSSCTSKSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 692 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010656-A | Application of oxyalkylisourea in introducing methyl and isotopically-labeled methyl | 陕西师范大学 | 2026-05-12 | — | — | CN | claimed |
| CN-119528812-B | Double amino acid-genipin derivative and preparation method and application thereof | 广东工业大学 | 2025-06-03 | — | — | CN | claimed |
| CN-119241385-B | Beta-acyloxy enamide derivative and preparation method and application thereof | 江西师范大学 | 2025-03-25 | — | — | CN | claimed |
| CN-119528812-A | Double amino acid-genipin derivative and preparation method and application thereof | 广东工业大学 | 2025-02-28 | — | — | CN | claimed |
| CN-119241385-A | Beta-acyloxy enamide derivative and preparation method and application thereof | 江西师范大学 | 2025-01-03 | — | — | CN | claimed |
| CN-118324850-B | Broad-spectrum macrolide compound and preparation and application thereof | 杭州贝普泰生物医药有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-118324850-A | Broad-spectrum macrolide compound and preparation and application thereof | 杭州贝普泰生物医药有限公司 | 2024-07-12 | — | — | CN | claimed |
| CN-113698457-B | Preparation method of gonadorelin acetate | 上海丽珠制药有限公司 | 2024-06-11 | — | — | CN | claimed |
| CN-118085005-A | 18 Beta-glycyrrhetinic acid derivative and preparation method and application thereof | 石河子大学 | 2024-05-28 | — | — | CN | claimed |
| CN-115724780-B | Acylthiourea compound based on hydrophobic tag, preparation method thereof and application of acylthiourea compound in resisting influenza A virus | 武汉大学 | 2024-04-26 | — | — | CN | claimed |
| CN-103214552-B | Synthesis and application of multi-site modified endomorphin-1 analogue | UNIV LANZHOU | 2015-01-21 | — | — | CN | claimed |
| CN-103214552-A | Synthesis and application of multi-site modified endomorphin-1 analogue | UNIV LANGZHOU | 2013-07-24 | — | — | CN | claimed |
| CN-102558297-B | Endomorphin-1 analogue modified by alpha-alkenyl-beta-amino acid and composition and application thereof | UNIV LANGZHOU | 2013-07-17 | — | — | CN | claimed |
| CN-102558297-A | Endomorphin-1 analogue modified by alpha-alkenyl-beta-amino acid and composition and application thereof | UNIV LANGZHOU | 2012-07-11 | — | — | CN | claimed |
| CN-100590068-C | Method for preparing primary amine carbon nano tube | UNIV TONGJI | 2010-02-17 | — | — | CN | claimed |
| CN-101177259-A | Method for preparing primary amine carbon nano tube | UNIV TONGJI (CN) | 2008-05-14 | — | — | CN | claimed |
| US-6951946-B2 | Large scale synthesis of 1,2,4- and 1,3,4-oxadiazole carboxylates | LEXICON PHARMACEUTICALS, INC. (US) | 2005-10-04 | — | — | US | claimed |
| US-20050154211-A1 | Large scale synthesis of 1,2,4- and 1,3,4- oxadiazole carboxylates | KOLB HARTMUTH C (US) | 2005-07-14 | — | — | US | claimed |
| US-20040019215-A1 | Large scale synthesis of 1,2,4- and 1,3,4-oxadiazole carboxylates | LEXICON PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | claimed |
| WO-1990006937-A1 | DERIVATIVES OF TETRAPEPTIDES AS CCK AGONISTS | ABBOTT LABORATORIES (US) | 1990-06-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154211-A1 | Large scale synthesis of 1,2,4- and 1,3,4- oxadiazole carboxylates | OXA1L, ODC1, CYP4B1 | ACE 1014/4885CTSL 4371/4885CTSS 2627/4885 |
| US-20040019215-A1 | Large scale synthesis of 1,2,4- and 1,3,4-oxadiazole carboxylates | OXA1L, ODC1, CYP4B1 | ACE 1014/4885CTSL 4371/4885CTSS 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.